白血病患儿腰椎穿刺的成功与并发症:生物阻抗针系统对比常规操作的随机交叉临床试验研究方案
本研究为多中心、随机、两臂交叉非劣效性试验,在儿童血液肿瘤患者常规临床流程中比较IQ-Tip生物阻抗脊柱针系统(研究臂A)与常规22G Quincke型脊柱针(研究臂B)的腰椎穿刺表现。每例患者穿刺顺序随机为ABAB或BABA,总穿刺次数至少300次,每例2至4次。主要结局为创伤性腰椎穿刺发生率、首次穿刺成功率和硬脊膜穿刺后头痛发生率。
要点
- 儿童急性淋巴细胞白血病长期生存率超过90%,但初始鞘内治疗时创伤性腰椎穿刺可降低无事件生存概率。
- 文献报道约五分之一儿童急性淋巴细胞白血病患者的腰椎穿刺为创伤性。
- 新型生物阻抗脊柱针系统在儿童急性淋巴细胞白血病患者中首次穿刺成功率为80%,创伤性腰椎穿刺发生率为11%。
核心结论
- 本研究将为新型生物阻抗脊柱针相比常规脊柱针在白血病患儿腰椎穿刺中的临床获益、性能和安全性提供科学证据。
研究设计与样本
- 多中心、随机、两臂交叉非劣效性试验,在儿童血液肿瘤患者的常规临床工作流程中实施。
- 每例入组患者的穿刺顺序随机分配为ABAB或BABA,研究臂A使用IQ-Tip系统,研究臂B使用常规Quincke型22G脊柱针。
- 总腰椎穿刺次数至少300次,每例患者穿刺次数为2至4次。
- 每次研究穿刺后立即记录表现,之后进行1周日记随访和4周记录随访,评估症状、并发症和不良事件。
- 试验注册号ISRCTN16161453,注册日期2022年7月8日。
主要发现
- 近期一种测量脊柱针尖端组织生物阻抗的新型医疗器械在儿童急性淋巴细胞白血病患者中可行。
- 该设备首次穿刺成功率为80%,创伤性腰椎穿刺发生率为11%。
- 文献报道创伤性腰椎穿刺涉及五分之一的儿童急性淋巴细胞白血病患者。
关键数值与推荐
- 主要结局为创伤性腰椎穿刺发生率、首次穿刺成功率和硬脊膜穿刺后头痛发生率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute lymphoblastic leukemia (ALL) is the most common malignancy diagnosed in children. At present, the long-term survival from pediatric ALL is well over 90%. However, the probability of event-free survival is reduced if the lumbar puncture (LP) procedures at the beginning of the patient's intrathecal therapy cause blood leakage into the spinal canal and blast cells contaminate the cerebrospinal fluid. According to the literature, such traumatic LP procedures concern one out of five pediatric patients with ALL. Recently, a novel medical device measuring the tissue bioimpedance at the tip of a spinal needle was found feasible in pediatric patients with ALL. The LP procedure was successful at the first attempt in 80% of procedures, and the incidence of traumatic LPs was then 11%. The purpose of the present study is to compare the bioimpedance spinal needle system with the standard clinical practice resting on a conventional spinal needle and investigate its efficacy in clinical practice. METHODS: The study is a multicenter, randomized, two-arm crossover noninferiority trial of pediatric hemato-oncology patients that will be conducted within the usual clinical workflow. Patients' LP procedures will be performed alternately either with the IQ-Tip system (study arm A) or a conventional Quincke-type 22G spinal needle (study arm B). For each enrolled patient, the order of procedures is randomly assigned either as ABAB or BABA. The total number of LP procedures will be at least 300, and the number of procedures per patient between two and four. After each study LP procedure, the performance will be recorded immediately, and 1-week diary-based and 4-week record-based follow-ups on symptoms, complications, and adverse events will be conducted thereafter. The main outcomes are the incidence of traumatic LP, first puncture success rate, and incidence of post-dural puncture headache. DISCUSSION: The present study will provide sound scientific evidence on the clinical benefit, performance, and safety of the novel bioimpedance spinal needle compared with the standard clinical practice of using conventional spinal needles in the LP procedures of pediatric patients with leukemia. TRIAL REGISTRATION: ISRCTN ISRCTN16161453. Registered on 8 July 2022.
引用
- Sievänen H, Kari J, Aarnivala H, et al. Success and complications in lumbar punctures of pediatric patients with leukemia: a study protocol for a randomized clinical crossover trial of a bioimpedance needle system versus conventional procedure. Trials. 2023. PMID: 37475006. doi:10.1186/s13063-023-07498-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。